Tissue Distribution and Cytochrome P450 Inhibition of Sesaminol and Its Tetrahydrofuranoid Metabolites

被引:11
|
作者
Jan, Kuo-Ching [2 ]
Chang, Yi-Wei [3 ]
Hwang, Lucy Sun [1 ]
Ho, Chi-Tang [1 ,4 ]
机构
[1] Natl Taiwan Univ, Grad Inst Food Sci & Technol, Taipei 10764, Taiwan
[2] Food Ind Res & Dev Inst, Hsinchu, Taiwan
[3] SunTen Phytotech Inc, Dept Res & Dev, Taipei, Taiwan
[4] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA
关键词
sesaminol; tetrahydrofuranoid lignans; tissue distribution; cytochrome P450; P-GLYCOPROTEIN; HUMAN LIVER; MULTIDRUG-RESISTANCE; DRUG-INTERACTIONS; SCHISANDRIN-B; LIGNANS; TRIGLUCOSIDE; RAT; ELIMINATION; MICROSOMES;
D O I
10.1021/jf302699f
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
Sesame lignans such as sesamin, sesaminol, and sesamolin are major constituents of sesame oil, and all have a methylenedioxyphenyl group and multiple functions in vivo. It was previously reported that sesaminol, a tetrahydrofurofuran type lignin, was metabolized to mammalian lignans. The present study examined the tissue distribution of sesaminol in Sprague-Dawley (SD) rats. Changes in the concentration of sesaminol and its metabolites (sesaminol glucuronide/sulfate, hydroxymethylsesaminol-tetrahydrofuran, enterolactone, and enterodiol) were determined in tissues within a 24 h period after tube feeding (po 220 mg/kg) to SD rats. The concentrations of enterodiol and enterolactone were significantly higher than those of sesaminol and its tetrahydrofuranoid metabolites in the organs (liver, heart, brain, and kidney). This study demonstrates that sesaminol has potent inhibition of cytochrome P450 (CYPs), compared to tetrahydrofuranoid metabolites. The IC50 values of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 for sesaminol were determined as 3.57, 3.93, 0.69, 1.33, and 0.86 mu M, respectively. In addition, hydroxymethylsesaminol-tetrahydrofuran and enterodiol were weak inhibitors of CYP2C9 and CYP1A2, respectively.
引用
收藏
页码:8616 / 8623
页数:8
相关论文
共 50 条
  • [31] Computational prediction of cytochrome P450 inhibition and induction
    Kato, Harutoshi
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : 30 - 44
  • [32] Human cytochrome P450 biocatalysts for the facile synthesis of metabolites
    Mayhew, MP
    Munir, I
    Bui, P
    Rozzell, D
    FASEB JOURNAL, 2006, 20 (04): : A263 - A264
  • [33] Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development
    Kandel, Sylvie E.
    Wienkers, Larry C.
    Lampe, Jed N.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 347 - 359
  • [34] Production of diclofenac metabolites by applying cytochrome P450 technology
    Kaluzna, Iwona
    Brummund, Jan
    Schuermann, Martin
    CHIMICA OGGI-CHEMISTRY TODAY, 2017, 35 (06) : 55 - 58
  • [35] Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology
    Fan, Fan
    Roman, Richard J.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (10): : 2845 - 2855
  • [36] Role of cytochrome P450 metabolites of arachidonic acid in hypertension
    Sarkis, A
    Roman, RJ
    CURRENT DRUG METABOLISM, 2004, 5 (03) : 245 - 256
  • [37] Cytochrome P450
    P. H. Roos
    N. Jakubowski
    Analytical and Bioanalytical Chemistry, 2008, 392 : 1015 - 1017
  • [38] Cytochrome P450
    Roos, P. H.
    Jakubowski, N.
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2008, 392 (06) : 1015 - 1017
  • [39] Cytochrome P450 metabolites of arachidonic acid in human placenta
    Schaefer, WR
    Werner, K
    Schweer, H
    Schneider, J
    Arbogast, E
    Zahradnik, HP
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 1997, 54 (04): : 677 - 687
  • [40] Cytochrome P450
    Poulos, TL
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 1995, 5 (06) : 767 - 774